Rogue Research (Us) Inc.

Rogue Research (Us) Inc., a for-profit corporation headquartered in Cambridge, Massachusetts, manufactures and supplies specialized neuroimaging, neuronavigation, and neuromodulation equipment to federal health research and clinical facilities as a prime contractor on small, sole-source purchase orders. The vendor operates exclusively in the prime role (100% of recent awards) with no subcontract footprint and competes on full-and-open procurements without set-aside designation, though one recent NINDS award structured the underlying solicitation to permit competition from 8(a), SDVOSB, HUBZone, SDB, VOSB, and WOSB firms before awarding on a non-set-aside basis.

Rogue Research's capability portfolio centers on turnkey neuroimaging and neuromodulation systems for research protocol support and clinical therapy. Equipment lines include BrainSight neuronavigation systems, BrightSight neuroimaging platforms with EMG integration, BrainWay transcranial magnetic stimulation (TMS) systems, motion-tracking camera components (Vega and POLARIS LYRA), and controllable TMS stimulators. Representative prime work includes a $120.5 thousand purchase order from the National Institute of Neurological Disorders and Stroke (NINDS) on June 19, 2026 for a controllable TMS stimulator with precise pulse-timing capability for protocol development; a $22.8 thousand Total Small Business set-aside purchase order from NINDS on September 4, 2026 for a Vega high frame-rate motion-tracking camera to restore BrainSight system functionality in TMS-Cobot robotic integration; and a $46.4 thousand sole-source purchase order from the National Institute of Mental Health on September 25, 2026 for two 16-channel preamplifier interface boxes to support 7T MRI neurophysiology imaging work in Ottawa, Ontario.

Customer concentration reflects a narrow federal healthcare footprint. The National Institute of Neurological Disorders and Stroke leads with three awards totaling $163 thousand combined potential value (88% of awards by funding-agency count); the Department of Veterans Affairs Veterans Health Administration accounts for three separate VISN units with $89 thousand combined potential value across the VA network; and the National Institute of Mental Health and Defense Health Agency round out the six distinct customer agencies. Awards are categorized across medical equipment wholesale and analytical instrument manufacturing (top NAICS codes), with laboratory equipment, medical and surgical instruments, and imaging supplies as primary PSC classifications.

Activity has grown from one award in 2022 to three in 2026; all eight awards are firm fixed-price purchase orders with 100% of combined potential value ($266 thousand) obligated. Three awards (combined potential value $143 thousand) face ultimate completion within the next twenty-four months, representing near-term recompete exposure. The vendor has not secured positions on government-wide vehicles, BPAs, or IDIQs; all work flows through direct agency purchase orders. Performance occurs at the Cambridge, Massachusetts headquarters and at customer sites including Ottawa, Fort Bliss, and VA facilities across multiple VISNs.